-
A Prescribed Digital Health App and Number of Migraine Days: A Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the prescribed digital migraine health app did not show superiority in reducing migraine days compared with a control app having only basic headache documentation features. This finding underscores the need for randomized clinical trials as a cornerstone of a robust evaluation framework, ensuring both treatment efficacy and… →
-
Pelvic floor examination in vulvodynia: VAMP protocol validation in correlation with central sensitization
CONCLUSIONS: The VAMP confirmed the presence of a painful vestibule, PFM, and paraurethra under pressure. The VAMP protocol was successfully cross-validated and effective in discriminating women with PFM overactivity, confirmed in almost all patients with vulvodynia. Half of the participants met the criteria for CS. The correlation between CSI and PFM pain on pressure suggests… →
-
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial
CONCLUSION: Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olaparib as new treatment options in patients with advanced or recurrent endometrial cancer and is the first to report on these… →
-
Effect of a New Skin-Lightening Cosmetic Containing Cordyceps Extract in the Treatment of Melasma: A Clinical Trial
CONCLUSIONS: Our study demonstrated that both oral TXA combined with hydroquinone cream and oral TXA combined with Cordyceps essence significantly improved melasma in women. However, the incidence of adverse reactions was lower with topical Cordyceps essence than that with hydroquinone cream. Cordyceps essence appeared to be a promising alternative for patients intolerant to hydroquinone cream.… →
-
9 Mistakes Leaders Make With AI Strategy
At the 2025 MIT Sloan CIO Symposium, many tech and business leaders voiced the same frustrations — about AI initiatives that aren’t delivering business value, pilot projects that never made it to production, and their ongoing struggle to figure out what’s going wrong. So we asked those leaders and AI experts in the room to… →
-
Why «I’m Sorry» Are Two of the Strongest Words for Leaders
Something goes wrong—a mistake, perhaps even a serious incident. What happens next defines not only personal character for a values-based leader, but also organizational culture. This is the power of a sincere apology. As my good friend and former chair and CEO of Medtronic, Inc., Art Collins, observed in our recent conversation on leadership and… →
-
When Memory Leads to Wrong Moves
When we have a critical decision to make, it’s natural to lean on our memory. After all, recalling past experiences could help us avoid old mistakes and steer us in the right direction, especially when facing a situation we’ve encountered before. “If the present looks a lot like the past, then of course you’d want… →
-
Knock Knock. Who’s There? Generative AI.
I told my plants I love them, and now they’re growing like they’re trying to escape. If you heard a comedian deliver that joke at a club, you might chuckle, or groan, or even toss out a heckle. But what if you found out the performer got the material from artificial intelligence rather than their… →
-
Fixing a Market Mismatch
Fiber internet is one the fastest and most reliable ways to connect to the internet, yet just over half of U.S. households have access to it. This lagging market for fiber internet is just one of many examples of how the market for certain products or services sometimes stubbornly refuses to form or reach its… →
-
Investment Transparency Encourages Copycats—and Creates Risks
Wall Street is full of copycats, from institutional investors eager to peek over their successful colleagues’ shoulders to retail investors who mimic the trades of luminaries like Warren Buffett and George Soros. In the United States insurance industry, transparency rules create a copycat’s paradise. Regulators require insurers to disclose not only their investment holdings, but… →